Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein
A method of treating or preventing an immune mediated disorder in a mammal, said method comprising the administration of a therapeutically effective amount of an estrogenic component to said mammal, wherein the estrogenic component is selected from the group consisting of: substances represented by the following formula: in which formula R 1 , R 2 , R 3 , R 4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; each of R 5 , R 6 , R 7 is a hydroxyl group; no more than 3 of R 1 , R 2 , R 3 , R 4 are hydrogen atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors. Another aspect of the invention relates to a pharmaceutical formulation comprising the aforementioned estrogenic component, an immunotherapeutic agent and a pharmaceutically acceptable excipient.
1. A method of treating or reducing the risk of developing an immune mediated disorder in a mammal, said immune mediated disorder being selected from the group consisting of multiple sclerosis; rheumatoid arthritis; and osteoarthritis, and said method comprising administering a therapeutically effective amount of an estrogenic component selected from the group consisting of a substance represented by
in which formula R 1 , R 2 , R 3 , R 4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; each of R 5 , R 6 , R 7 is a hydroxyl group; no more than 3 of R 1 , R 2 , R 3 , R 4 are hydrogen atoms;
precursors capable of liberating a substance according to the aforementioned formula, which precursors are derivatives of the estrogenic substances wherein the hydrogen atom of at least one of the hydroxyl groups has been substituted by an acyl radical of a hydrocarbon carboxylic, sulfonic acid or sulfamic acid of 1-25 carbon atoms; tetrahydrofuranyl; tetrahydropyranal; or a straight or branched chain glycosydic residue containing 1-20 glycosidic units per residue; and
mixtures of one or more of the aforementioned substances and/or precursors.
2. The method according to claim 1 , wherein R 3 represents a hydroxyl group or an alkoxy group.
3. The method according to claim 1 , wherein 3 of the groups R 1 , R 2 , R 3 , and R 4 represent hydrogen atoms.
4. The method according to claim 1 , wherein the estrogenic component exhibits an 8β, 9α, 13β, 14α configuration of the steroid-skeleton.
5. The method according to claim 1 , wherein the method comprises the uninterrupted administration of the estrogenic component during a period of at least 5 days.
6. The method according to claim 1 , wherein the method comprises oral or subcutaneous administration of the estrogenic component.
7. The method according to claim 6 , wherein the method comprises oral administration.
8. The method according to claim 1 , wherein the estrogenic component is administered in an amount of at least 1 μg per kg of bodyweight per day.
9. The method according to claim 1 , wherein the immune mediated disorder is a T-lymphocyte mediated disorder and/or a chronic inflammatory disease.
10. The method according to claim 9 , wherein the immune mediated disorder is a Th1 mediated disorder.
11. The method according to claim 1 , wherein estrogenic component is administered orally.
12. The method according to claim 1 , wherein the method is for treating the immune mediated disorder in the mammal.